ATE414519T1 - Kombination aus einem nmda-antagonist und acetylcholinesterase-hemmern zur behandlung der alzheimer-krankheit - Google Patents

Kombination aus einem nmda-antagonist und acetylcholinesterase-hemmern zur behandlung der alzheimer-krankheit

Info

Publication number
ATE414519T1
ATE414519T1 AT03724895T AT03724895T ATE414519T1 AT E414519 T1 ATE414519 T1 AT E414519T1 AT 03724895 T AT03724895 T AT 03724895T AT 03724895 T AT03724895 T AT 03724895T AT E414519 T1 ATE414519 T1 AT E414519T1
Authority
AT
Austria
Prior art keywords
alzheimer
disease
treatment
combination
acetylcholinesterase inhibitors
Prior art date
Application number
AT03724895T
Other languages
English (en)
Inventor
Lars Thomsen
Anders Pedersen
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29713304&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE414519(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Application granted granted Critical
Publication of ATE414519T1 publication Critical patent/ATE414519T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
AT03724895T 2002-05-31 2003-05-22 Kombination aus einem nmda-antagonist und acetylcholinesterase-hemmern zur behandlung der alzheimer-krankheit ATE414519T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38446702P 2002-05-31 2002-05-31
DKPA200200844 2002-05-31

Publications (1)

Publication Number Publication Date
ATE414519T1 true ATE414519T1 (de) 2008-12-15

Family

ID=29713304

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03724895T ATE414519T1 (de) 2002-05-31 2003-05-22 Kombination aus einem nmda-antagonist und acetylcholinesterase-hemmern zur behandlung der alzheimer-krankheit

Country Status (17)

Country Link
EP (1) EP1509232B1 (de)
JP (1) JP2005528431A (de)
AT (1) ATE414519T1 (de)
AU (1) AU2003227516B2 (de)
BR (1) BR0311375A (de)
CY (1) CY1108725T1 (de)
DE (1) DE60324788D1 (de)
DK (1) DK1509232T3 (de)
ES (1) ES2314200T3 (de)
IL (1) IL165255A0 (de)
MX (1) MXPA04011762A (de)
NO (1) NO332754B1 (de)
NZ (1) NZ536603A (de)
PL (1) PL373903A1 (de)
PT (1) PT1509232E (de)
SI (1) SI1509232T1 (de)
WO (1) WO2003101458A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04006900A (es) * 2002-10-24 2004-10-15 Merz Pharma Gmbh & Co Kgaa Politerapia que utiliza derivados de 1-aminociclohexano e inhibidores de acetilcolinesterasa.
US20060020042A1 (en) * 2004-01-05 2006-01-26 Forest Laboratories, Inc. Memantine for the treatment of mild and mild to moderate Alzheimer's disease
EP1708707A1 (de) * 2004-01-22 2006-10-11 Neurosearch A/S Pharmazeutische zusammensetzung mit einem monoamin-neurotransmitter-wiederaufnahmehemmer und einem n-methyl-d-aspartat (nmda)-rezeptorantagonisten
TW200531680A (en) * 2004-03-03 2005-10-01 Merz Pharma Gmbh & Co Kgaa Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease
WO2005092009A2 (en) * 2004-03-19 2005-10-06 Axonyx, Inc. Acetylcholinesterase inhibitors and n-methyl-d-aspartate antagonists useful in the treatment of cognitive disorders
EP1827385B1 (de) * 2004-11-23 2013-03-27 Adamas Pharmaceuticals, Inc. Pharmazeutische zusammensetzung enthaltend memantin in verzögerter freisetzungs-form zur behandlung von dementia
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
JP5666087B2 (ja) 2005-04-06 2015-02-12 アダマス・ファーマシューティカルズ・インコーポレーテッド Ｃｎｓ関連疾患の治療のための方法及び組成物
EP1878444B1 (de) * 2005-04-28 2015-09-09 Eisai R&D Management Co., Ltd. Zusammensetzung mit einem arzneimittel gegen demenz
TWI389709B (zh) * 2005-12-01 2013-03-21 Novartis Ag 經皮治療系統
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
WO2008065141A1 (en) 2006-11-30 2008-06-05 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
ZA200905537B (en) 2007-03-01 2010-10-27 Probiodrug Ag New use of glutaminyl cyclase inhibitors
JP5667440B2 (ja) 2007-04-18 2015-02-12 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
MX2012002993A (es) 2009-09-11 2012-04-19 Probiodrug Ag Derivados heterociclicos como inhibidores de ciclasa glutaminilo.
CA2782556C (en) 2009-12-02 2018-03-27 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
CA2789014C (en) 2010-02-09 2019-01-15 Michela Gallagher Methods and compositions for improving cognitive function
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
MX2012010470A (es) 2010-03-10 2012-10-09 Probiodrug Ag Inhibidores heterociclicos d ciclasa de glutaminilo (qc, ec .3 2. 5).
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
AU2011276036B2 (en) 2010-07-05 2014-05-22 Gambro Lundia Ab An ambulatory ultrafiltration device, related methods and a computer program product
TR201007110A2 (tr) 2010-08-25 2012-03-21 Bi̇lgi̇ç Mahmut Sinerjik etki gösteren kombinasyonlar
WO2012048871A1 (en) 2010-10-12 2012-04-19 Merz Pharma Gmbh & Co. Kgaa Memantine for improving cognitive performance in subjects
WO2012123563A1 (en) 2011-03-16 2012-09-20 Probiodrug Ag Benz imidazole derivatives as inhibitors of glutaminyl cyclase
FR2983732B1 (fr) * 2011-12-09 2013-11-22 Servier Lab Nouvelle association entre le 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}pharmaceutiques qui la contiennent
WO2013160728A1 (en) * 2012-04-26 2013-10-31 Alma Mater Studiorum - Universita' Di Bologna Dual targeting compounds for the treatment of alzheimer's disease
WO2014035355A1 (en) * 2012-08-31 2014-03-06 Mahmut Bilgic Pharmaceutical combination comprising idebenone and memantine
WO2014055047A1 (en) * 2012-08-31 2014-04-10 Mahmut Bilgic Combination of idebenone and donezepil
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神***病を処置するための方法および組成物
AP2015008498A0 (en) * 2012-12-13 2015-05-31 Lundbeck & Co As H Compositions comprising vortioxetine and donepezil
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
CA2904767C (en) 2013-03-15 2022-06-21 Agenebio, Inc. Methods and compositions for improving cognitive function
WO2014204933A1 (en) 2013-06-17 2014-12-24 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
WO2016191288A1 (en) 2015-05-22 2016-12-01 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
MA45002B1 (fr) * 2016-05-18 2020-10-28 Suven Life Sciences Ltd Triple combinaison d'antagonistes purs du récepteurs 5-ht6, d'inhibiteurs de l'acétylcholinestérase et d'antagonistes du récepteur nmda
GB201614834D0 (en) * 2016-09-01 2016-10-19 Wista Lab Ltd Treatment of dementia
KR101938872B1 (ko) * 2016-09-30 2019-01-16 주식회사 바이오파마티스 도네페질 또는 그의 약학적으로 허용 가능한 염 및 메만틴 또는 그의 약학적으로 허용 가능한 염을 함유하는 치매 및 인지기능 장애 예방 또는 치료용 약학 조성물 및 이의 제조방법
US20190269627A1 (en) * 2016-10-28 2019-09-05 Chase Pharmaceuticals Corporation Memantine combinations and use
TR201619184A2 (tr) 2016-12-22 2018-07-23 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Donepezi̇l ve memanti̇n i̇çeren kapsül bi̇leşi̇mleri̇
EP3461819B1 (de) 2017-09-29 2020-05-27 Probiodrug AG Hemmer der glutaminylcyclase
PT3843702T (pt) 2019-05-31 2023-10-13 Tecnimede Soc Tecnico Medicinal Lda Combinação de dose fixa de libertação imediata de memantina e donepezilo

Also Published As

Publication number Publication date
NO20045434L (no) 2004-12-13
DE60324788D1 (de) 2009-01-02
CY1108725T1 (el) 2014-04-09
EP1509232B1 (de) 2008-11-19
SI1509232T1 (sl) 2009-04-30
NZ536603A (en) 2007-06-29
DK1509232T3 (da) 2009-02-23
WO2003101458A1 (en) 2003-12-11
MXPA04011762A (es) 2005-03-31
AU2003227516A1 (en) 2003-12-19
IL165255A0 (en) 2005-12-18
BR0311375A (pt) 2005-03-15
ES2314200T3 (es) 2009-03-16
PL373903A1 (en) 2005-09-19
JP2005528431A (ja) 2005-09-22
NO332754B1 (no) 2013-01-07
AU2003227516B2 (en) 2008-03-20
EP1509232A1 (de) 2005-03-02
PT1509232E (pt) 2009-01-07

Similar Documents

Publication Publication Date Title
ATE414519T1 (de) Kombination aus einem nmda-antagonist und acetylcholinesterase-hemmern zur behandlung der alzheimer-krankheit
ATE443043T1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
BR0308243A (pt) Composto, formulação farmacêutica, e, métodos de tratar diabetes, doença de alzheimer, e de inibir gsk-3 em um mamìfero
ATE430555T1 (de) Pharmazeutische zusammensetzungen zur behandlung von asthma
MA25809A1 (fr) Derives d'arylmethylamine pour usage comme inhibiteurs de tryptase
GEP20053600B (en) 3-(4-Amidopyrrol-2-Ylmethlidene)-2- Indolinone Derivatives as Protein Kinase Inhibitors
ATE371656T1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
ATE416761T1 (de) Prävention und behandlung von durch entzündung ausgelöstem und/oder immunvermitteltem knochenschwund
BR0316350A (pt) Diaminotriazóis úteis como inibidores de proteìna cinases
ATE512163T1 (de) Verabreichung von mitteln zur behandlung von entzündungen
ATE334668T1 (de) Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
MXPA04002167A (es) Inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes.
GB0223040D0 (en) Therapeutic compounds
CY1106927T1 (el) Φαρμακευτικη συνθεση ενος pde4 ή pde3/4 αναστολεα και ανταγωνιστη υποδοχεα ισταμινης
EA200201276A1 (ru) Производные арилметиламина для использования в качестве ингибиторов триптазы
ATE357438T1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
IS6087A (is) N-(2-fenýl-4-amínó-bútýl)-1-naftamíð sem virka á móti taugakínín-1 viðtaka
DE60134735D1 (de) Neue neurokinin-antagonisten zum gebrauch als arzneimittel
DE69917005D1 (de) Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung
ATE425756T1 (de) Verwendung von carbamazepinderivaten zur behandlung von agitatio in demenspatienten
ATE308513T1 (de) Naphthamid-neurokinin antagonisten zur verwendung als medikamente
ATE420860T1 (de) N-substituierte amide als nk1 rezeptor antagonisten
NO20033634L (no) GLyT-1-inhibitorer
EA200401617A1 (ru) Комбинация nmda-антагониста и ингибиторов ацетилхолинэстеразы для лечения болезни альцгеймера
DE60122764D1 (de) Verwendung von cortisol-sequestriermitteln zur behandlung von hypercortisolaemie-verwandten erkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1509232

Country of ref document: EP